Exclusive-New data show most US patients now stay on Wegovy, Zepbound after a year
By Chad Terhune
LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
That level of persistence is higher than what prior analyses have shown, suggesting that more patients might be staying on the popular GLP-1 drugs for obesity as product shortages ease, insurance coverage expands and doctors manage side effects better, health experts say.
Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 were still taking them 12 months later. For Wegovy, that was up significantly from 40% who started therapy in 2023 and 34% who began three years ago in this analysis by Prime Therapeutics, a pharmacy benefits manager (PBM).
Patrick Gleason, Prime's assistant vice president for health outcomes and a co-author of the analysis, said he was surprised to see persistence rise above 50%.
"It's a near doubling from one-third persistent to roughly two-thirds now," Gleason said. "This is a dramatic change, and I believe this is more reflective of what we will see going forward."
Zepbound's results were relatively unchanged year over year, though the number of U.S. patients starting on the medication in 2023 was limited since it did not launch until November of that year. Wegovy was approved in June 2021.
The analysis shared with Reuters does not include details about why patients continued or stopped therapy. Some people have reported stopping because the drugs became unaffordable or their insurance no longer covered them. Others quit due to common gastrointestinal side effects, inability to get refills due to supply shortages or achievement of their weight-loss goal, among other factors.
Studies have shown that most patients who quit their GLP-1 drugs usually regain most of the weight. The medications may require extended use to yield meaningful benefits for patients' health.
Many employers and government agencies remain wary of adding coverage for these highly effective, but expensive medicines due to the significant upfront investment and uncertainty about any future savings.
Dr. Ezekiel J. Emanuel, co-director of the Healthcare Transformation Institute at the University of Pennsylvania, said low persistence on these weight-loss drugs had been concerning and the new data might indicate that increased insurance coverage is helping to turn the tide.
Novo declined to comment on the data, and Lilly did not immediately respond to a request for comment.
Prime is owned by 19 U.S. Blue Cross and Blue Shield health insurance plans and manages pharmacy benefits for about 73 million people.
LONGER TERM DIVERGENCE
In its analysis, Prime reviewed pharmacy and medical claims for 23,025 people with commercial health plans who received prescriptions for either Wegovy or Zepbound and had a diagnosis of obesity.
Prime excluded patients with a diabetes diagnosis in their medical claims or who were using a drug for type 2 diabetes, for which these GLP-1 medicines were originally developed. The mean age of patients in the year-over-year analysis was 46 and 77% were female.
Patients were deemed persistent with their medication if they had no 60-day gaps in supply. The data allowed for switching among GLP-1 products.
The data does not include patients who took compounded versions of the weight-loss drugs or paid for their prescription out of pocket outside of insurance.
Prime also did a separate analysis of longer-term use. Only 14% of patients were still taking Wegovy after three years, the data show. That was a drop from 24% on Wegovy at the two-year mark.
That longer-term analysis examined 5,780 patients who had remained enrolled in their health insurance for three years and did not have type 2 diabetes.
The U.S. Food and Drug Administration removed semaglutide, the active ingredient in Wegovy, from its shortage list earlier this year and did the same for tirzepatide, the active ingredient in Zepbound, in December. Those moves eventually barred compounding pharmacies from making cheaper copies of the weight-loss drugs.
Some patients have purchased these weight-loss medications directly from the drugmakers outside of their health insurance. Those prescriptions were not tracked in this analysis and that cohort of patients may behave differently, said David Lassen, Prime's vice president of clinical pharmacy services.
"That group could have a different adherence pattern," Lassen said. "That's something we want to continue to watch."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
35 minutes ago
- Medscape
Insurers' New Prior Authorization Pledge Draws Skepticism
As US health insurers promote a new joint plan to overhaul prior authorization (PA) as a major advance, clinician and patient advocates say insurers have provided few specifics about what will change and how they'll be held accountable. For example, the voluntary plan unveiled on Monday promises that insurers will reduce the PA burden on providers and patients, but no numbers are provided. And insurers only pledged to 'work' toward overhauling the electronic PA system with a goal of implementation by 2027. 'There are some incremental things that go above and beyond what they're required to do, but there are few concrete commitments,' California-based consultant and former healthcare executive Seth Glickman, MD, MBA, told Medscape Medical News . 'There's not a lot here to ensure their actions are going to match their words.' Glickman also highlighted what he called a 'one-sided' accompanying report by the America's Health Insurance Plans (AHIP) trade association that defends PA as a 'critical safeguard in patient care,' says it 'is only selectively used,' and blames 'a number of physicians' who don't follow evidence-based medicine. The growing use of PA to reflexively deny healthcare has sparked outrage from clinicians and patients, leading to action from state and federal lawmakers. The American Society of Clinical Oncology has tracked more than 110 PA bills in 40 states. The 2024 assassination of UnitedHealthCare CEO Brian Thompson spotlighted the burdens insurers have placed on patients and providers. 'There's violence in the streets over these issues," said Mehmet Oz, MD, MBA, administrator of the Centers for Medicare and Medicaid Services (CMS), at a press conference announcing the new PA reform plan. 'This is not something that is a passively accepted reality anymore — Americans are upset about it.' Here's a closer look at the PA reform plan and the reaction from the medical community. A Framework to 'Simplify' PA AHIP announced on Monday that leading commercial, Medicare Advantage, and Medicaid managed care coverage insurers covering 257 million Americans will voluntarily 'simplify' PA. 'For patients, these commitments will result in faster, more direct access to appropriate treatments and medical services with fewer challenges navigating the health system,' an AHIP press release said. 'For providers, these commitments will streamline prior authorization workflows, allowing for a more efficient and transparent process overall, while ensuring evidence-based care for their patients.' Specifically, insurers agreed to: Aim to release a framework by January 1, 2027, that will ' work toward implementing common, transparent submissions for electronic prior authorization.' As the AHIP's own report noted, an insurer survey found that 'almost half of prior authorization requests are submitted manually by phone, fax, or mail.' Reduce PA requirements in fully insured, ACA Marketplace and Medicare Advantage coverage, 'with demonstrated reductions' by January 1, 2026. The plans 'further commit that they will provide data to allow industry reporting of the extent of such reductions reflecting actions taken since January 2024.' There's no specific goal for reduction of PA requirements. According to an AHIP survey, 96% of prescription drug claims and 93% of medical claims are not subject to PA. However, a 2025 KFF report found that 'virtually all enrollees in Medicare Advantage (99%) are required to obtain prior authorization for some services.' Real-Time Responses and Limiting Use of Artificial Intelligence (AI) The plans also agreed to: Honor previous PA authorizations for benefit equivalent in-network services during 90-day transition periods between plans as of January 1, 2026. Medicare Advantage plans are currently required to provide a variation of this. By January 1, 2026, 'provide clear, easy-to-understand explanations of prior authorization determinations, including support for appeals and guidance on next steps.' According to the AHIP survey, commercial plans have PA denial rates of 3% for medical services and 10% for prescription medicines. The KFF report about Medicare Advantage plans found that insurers fully or partially denied 6.4% of PA requests in 2023, and 11.7% of those requests were appealed. While appeals were rare, 81.7% were partially or fully overturned. 'Commit to an acceleration of the percentage of prior authorization requests for medical services answered in real time if submitted electronically by providers with all necessary clinical documentation. By 2027, for all coverage types, at least 80% of prior authorization approvals will be answered in real time.' According to the AHIP survey, about 20% of current PA requests for medical services are approved in real time; the data for prescription medications were not provided. 'Affirm that all non-approved requests based on clinical reasons will continue to be reviewed by medical professionals — a standard already in place.' The AHIP survey says all responding health plans said, 'AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations.' Insurers Are Responding to Pressure Glickman, the consultant, said efforts to 'put a face and a name to the people who are impacted by prior authorization requirements and denials of care' have made a difference. He added that the Biden Administration helped pave the way for changes at the federal level. 'It would be disingenuous,' he said, for the Trump Administration 'to say they're the ones setting the priorities.' However, the Trump Administration now has the power to force changes in PA requirements. 'We're throwing money away on administrative costs financially. We're also wasting people's time,' Oz said, according to NBC Chicago. 'The most important reality is the administration has made it clear we're not going to tolerate it anymore. Either you fix it, or we're going to fix it. They wisely decided they should fix it.' Medical Organizations Respond Cautiously Medical organizations support the announced reforms — but also called for more than promises. 'Patients and physicians will need specifics demonstrating that the latest insurer pledge will yield substantive actions to bring immediate and meaningful changes, break down unnecessary roadblocks, and keep medical decisions between patients and physicians,' said Bobby Mukkamala, MD, president, American Medical Association, in a statement. Chet Speed, JD, chief policy officer of the American Medical Group Association, told Medscape Medical News that 'the vast majority of PA denials are an inefficient, bureaucratic exercise.' As he noted, researchers have found that high rates of denials are overturned on appeal. And a 2022 federal analysis of a small group of Medicare Advantage PA denials found that 13% would have been cleared under traditional Medicare. Speed also highlighted a 2022 American Medical Association survey of 1000 physicians that found 94% of physicians said PA at least sometimes leads to delays in care, and 7% said it 'resulted in a serious adverse event leading to a patient's disability, permanent bodily damage, congenital anomaly, birth defect, or death.' 'Anecdotally, we have heard from medical groups and systems that this delay is especially problematic on Fridays when PA offices close for the weekend,' Speed said, 'meaning patients stay in the hospital when a transfer to a post-acute setting would have been more clinically appropriate.' As for the new reform plan, Speed said 'the big deal' is that the White House, Department of Health and Human Services, and CMS support it. 'We believe the plan is a good first step,' he said, although he acknowledged that its details about reducing PA burden are 'vague.' Experts Weigh in With Skepticism — and Hope Kaye Pestaina, JD, director of the Program on Patient and Consumer Protections at KFF, told KFF Health News that she's not sure how the reform plan changes the fact that many patients don't realize they need PA until it's denied. 'So much of the prior authorization process is behind the black box,' she said. Adam Gaffney, MD, MPH, a critical care physician and assistant professor at Harvard Medical School, Boston, was skeptical too. He told NBC News that the plan is 'going to streamline it [PA] in some incremental ways only.' Sabin Dang, MD, a retinal specialist in St. Louis, told Medscape Medical News that the plan won't solve all PA problems. However, 'one of the things I'm most excited about is real-time answers, using technology to get answers while patient is sitting in the chair and then start the treatment process,' he said. This is much better than forcing patients to wait a week 'while they're suffering with decreased vision,' he added. Last year, Dang led a study that found 96.2% of PA requests for 2225 anti-VEGF drugs were approved, but most — 59.6% — remained unresolved after 24 hours. Most requests resulted in a delay of care, and an analysis showed that staff members needed to spend a median of 100 minutes on each request. The standardizing of PA technology will also be helpful, Dang said. 'We have many digital tools and websites to visit,' he said, although he added that fixing the system will be a 'huge logistical hurdle.' For his part, consultant Glickman said instant approvals raise questions about the true purpose of PA. 'If they're going to be auto-authorized, why are we requiring providers to jump through all these hoops to get authorization in the first place?'
Forbes
an hour ago
- Forbes
InnovationRx: Health Insurers Vow To Improve Prior Authorization (Again)
In this week's edition of InnovationRx, we look at efforts to improve prior authorization, commercializing Bell Labs' IP portfolio, a new billionaire from Caris Life Sciences' IPO, a big funding round for robots to do cataract surgery, and more. To get it in your inbox, subscribe here . AFP via Getty Images On Monday, representatives from multiple health insurance companies said they had pledged to the Department of Health and Human Services that they would improve their prior authorization procedures, the bureaucratic process required for them to pay for certain tests, medications or procedures. The insurers vowed to reduce the number of claims subject to prior authorization, standardize electronic requests for them and offer 90% of approvals in real time by 2027. This isn't the first time the industry has pledged to streamline the prior authorization process. Insurers made a similar pledge during the first Trump Administration in 2018, with some of those promises echoing language in the current announcement. When Centers for Medicare & Medicaid Services Administrator Mehmet Oz was asked at a press event why he thought this effort could work when others have failed, he replied that 'there is violence in the streets over these issues now,' presumably alluding to the murder of UnitedHealthcare CEO Brian Thompson last December. The technology is better now, too, he said, and the Administration plans to back the efforts with regulation. 'Either you fix it, or we'll fix it,' Oz told the insurance company execs. Bell Labs Is Commercializing Its Historic IP Portfolio, Starting With Healthcare Nishant Batra, Nokia's chief strategy and technology officer, has made commercializing Bell Labs' IP a priority. Nokia For decades, Bell Labs' research was legendary–an innovation factory that spawned transistors, lasers and solar cells. But its researchers were always better at ideas than commercialization. Even today, lots of patents and research ideas remain tucked away in its suburban New Jersey offices. Since joining Nokia in 2021, chief strategy and technology officer Nishant Batra has been working to change that. He told Forbes that when he kicked off the commercialization effort, he thought he could spin out two or three companies a year, but now thinks he may be able to do three to five. 'The world wouldn't exist without Bell Labs, but what Bell Labs does not do well is monetization,' Batra told Forbes. A big part of the effort to change that comes with a partnership with deep tech investor Celesta, which has $1.1 billion in assets under management and with whom Nokia has co-invested in the past. The two are scouring Bell Labs' IP portfolio for pieces of technology that might have commercial applications – and the first spinout is in healthcare. That first company, called Astranu, spun out in May with a small amount of seed funding, to apply Bell Labs' imaging technology known as integrated optical coherence tomography to diagnostics of middle ear conditions. It ultimately hopes to transform ear diagnostic care with advanced, non-invasive, high-resolution 3D imaging by reducing the need for exploratory surgery and expensive MRIs 'We built this technology for optical use, for communications,' Batra said. But as Bell Labs' researchers and Celesta's investors analyzed the technology, they realized what was built for communications could be applied to creating an accurate, handheld test for the middle ear. 'Our researchers on optical said, 'this is a good application,' and our friends at Celesta said, 'we can take this to market with you,'' Batra said. Most of this hidden-away IP won't be healthcare-related, but it's intriguing that the first company to launch from the Bell Labs' portfolio is, which not only shows the breadth of its research applications, but also how many technology innovations can be adapted to help patients. 'We call it 'bioconvergence,'' said Celesta's founding managing partner Sriram Viswanathan, noting how miniaturization of technology could be extremely helpful for medical applications. 'It's the intersection of advanced AI and semiconductor-related technologies as it applies to life sciences and biotech. Think about it as diagnostics more than therapeutics….There are so many applications in the healthcare area that we see this as a natural.' BIOTECH AND PHARMA Drugmaker Novo Nordisk said on Monday that it was ending its arrangement to sell its weight-loss drug, Wegovy, through telehealth provider Hims & Hers. The pharmaceutical company accused Hims & Hers of using 'deceptive marketing' to sell knockoff versions of its drug in a statement. The stock price of Hims & Hers collapsed shortly after the announcement, cutting its market capitalization by nearly one-third to a recent $9.6 billion, pummeling the fortune of cofounder and CEO Andrew Dudum , who is no longer a billionaire. Plus : A study published in the Journal of Immunology identified a biomarker that helps predict whether colorectal patients will respond to treatment using cytokine-induced killer cells. DIGITAL HEALTH AND AI Last week, precision medicine company Caris Life Sciences went public, minting a new billionaire in founder David Dean Halbert. At the company's recent market cap of $7.4 billion, Halbert is worth at least $3.3 billion by Forbes calculations. He owns nearly 44% of the company. 'I fundamentally believed that if there was something wrong with the human body, there was something misfiring at the molecular level and technology advances could find that and diagnose it and possibly treat it,' Halbert told Forbes. Read more here. Plus : Medical scribing startup Abridge reached a valuation of $5.3 billion after raising $300 million in venture funding led by Andreessen Horowitz. The Pittsburgh-based company has surged as doctors and health systems have adopted ambient listening apps, and the new valuation is nearly double the $2.75 billion it was worth when it last raised funds in February. Cofounder and CEO Shiv Rao told Forbes that he 'wasn't surprised per se' by the new valuation because of how quickly AI is changing the way companies operate. Abridge is expanding from using ambient listening to improve the doctor-patient relationship to using the technology to help health systems with their billing and coding. 'Why we have raised capital and invested so heavily in R&D is that we are taking our models to revenue school and risk-adjustment school,' he said. MEDTECH Cataract surgery is one of the world's most common medical procedures, with more than 4 million of them done each year in the United States alone, but there simply aren't enough doctors available to meet the demand for everyone who needs the surgery. Enter robotics. An Israeli startup is betting that robots can ultimately do it better and cheaper than human doctors. ForSight Robotics on Tuesday said it had raised $125 million led by Eclipse Ventures to expand its robotic platform, called Oryom, which it says is the world's first for cataracts and other eye diseases. The funding represents one of the largest investments in a surgical robotics startup, and brings ForSight's total investment to $195 million. 'At first people were intimidated by robotics' advancement,' Dr. Joseph Nathan, ForSight's cofounder, president and chief medical officer, told Forbes. 'Now they are seeing robotics as the things that will get them the best outcomes.' Read more here. PUBLIC HEALTH AND HOSPITALS The CDC's Advisory Committee on Immunization Practices (ACIP), which makes recommendations for vaccine practices, is scheduled to meet today and tomorrow to discuss vaccines for COVID-19, flu and RSV. Senator Bill Cassidy, R-La., a physician who chairs the Health, Education, Labor and Pensions Committee, called for the panel to be delayed, citing the lack of expertise among the new appointees of HHS Secretary Robert F. Kennedy Jr. and the fact that it includes fewer members than is typical. RFK Jr. purged the vaccine advisory committee earlier this of the committee's new members have expressed skepticism about vaccines, in keeping with his own views. But a new poll from the Harvard Opinion Research Program found these attitudes to be out-of-step with the vast majority of Americans. The survey found that 79% of Americans believe that parents should be required to vaccinate their children in order to attend school, and that even among Republicans 66% held this view. Among the remainder who didn't support mandatory vaccinations, 60% believed vaccines to be safe and effective–they just prefer to leave the choice up to parents. Plus : The American Cancer Society released the latest version of its Cancer Atlas today, which found that "an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors" and urged public health officials to accordingly focus on prevention. WHAT WE'RE READING People with severe diabetes were cured in a small trial of a new stem cell-based infusion from Vertex Pharmaceuticals. The GOP is pushing Medicaid work requirements even though similar efforts in Georgia and Arkansas have fallen flat. Changes at federal health agencies leave experts concerned that the U.S. is in worse shape to handle a new pandemic than it was before 2020. Researchers say that their studies were misrepresented by Health and Human Services to unjustifiably support anti-vaccine conclusions in a memo to Congress. Arine, which has developed an AI-powered platform for medication management, raised $30 million in venture funding led by Town Hall Ventures. A new flu drug could be better than a vaccine. In a small phase 2 study, a drug developed by Cidara Therapeutics offered 76.1% protection against catching the flu versus a placebo, higher protection than many flu vaccines. MORE FROM FORBES Forbes The 36 Colleges Most At Risk From Pell Grant Cuts By Fiona Riley Forbes US And Israel Should Prepare For Destructive Iranian Cyberattacks, Ex-Intel Officer Says By Thomas Brewster Forbes How New Balance Went From 'Dad Shoe' To Scoring The No. 1 NBA Draft Prospect By Justin Birnbaum
Gizmodo
an hour ago
- Gizmodo
This Experimental Tech Allows Surgeons to See Through Blood
Invisible Man, eat your heart out. In a first, scientists have just found a way for surgeons to see through blood during a procedure, effectively making it transparent. On Tuesday, Ocutrx Technologies revealed the innovative tool, named HemoLucence. It reportedly uses AI-powered physics to digitally visualize blood as though it were translucent, which should give surgeons a clear view of the tissue beneath while operating. The technology is part of a surgical microscope system that the company plans to test in clinical trials as early as this year. 'Having the ability to render blood 'transparent' now makes the unseen, in the heat of surgical battle, seen, creating another layer of safety and confidence for surgeons that traditional visual aids can't provide,' said Leonel Hunt, medical advisor at Ocutrx and an attending surgeon at Cedars-Sinai Spine Center and Cedars-Sinai Orthopedic Center in Los Angeles, in a statement from the company. Researchers at Ocutrx's R&D division, Genius Labs, developed HemoLucence. It's intended to 'overcome blood opacity through advanced computational physics.' The researchers will use this physics to understand how light behaves when it passes through areas filled with blood. With the information collected from images of the surgical site at different angles, algorithms then reconstruct in real time what these areas should look like underneath the blood, without surgeons needing to worry about sucking up or flushing out the blood. In tests so far, HemoLucence has been able to visualize areas covered by roughly a quarter inch of human blood, though the company expects the tech will soon reach up to a half inch of blood. 'The ability to render blood as transparent will provide a level of visualization not previously possible in any field of surgery. No matter the discipline or scale, bleeding is a regular part of any surgery and can create several challenges,' said Robert Louis, a neurosurgeon and director of the Skull Base and Pituitary Tumor Program at Hoag Memorial Hospital in California, in a statement from the company. 'This breakthrough helps overcome those challenges and is a significant step forward in making surgery safer and more efficient.' The company debuted HemoLucence this week at Abu Dhabi Global Health Week 2025. And a brief video of how it works can be seen here. But it will still take some time before you can expect to see it in a real-world operating room. The tech is a feature of the company's OR-Bot 3D Surgical Microscope System, and clinical trials of the microscope are scheduled to begin either this year or next. It's not quite Superman's X-ray vision, but it's still pretty impressive for us mere mortals.
